This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
CONTEXT Children with Prader-Willi syndrome ( PWS ) may have obesity and an abnormal body composition with a high body fat percentage , even if they have a normal body weight . Adiponectin has been inversely related to obesity and insulin resistance . OBJECTIVE The objective of the study was to evaluate in prepubertal PWS children the following : 1 ) adiponectin levels , body composition , carbohydrate metabolism , and triglyceride levels ; 2 ) associations between adiponectin and body composition , carbohydrate metabolism , and triglycerides ; and 3 ) effects of GH treatment on these outcome measures . PATIENTS Twenty prepubertal PWS children participated in the study . INTERVENTION The subjects were r and omized into a GH treatment group ( n=10 , 1 mg/m2.d ) and a non-GH-treated control group ( n=10 ) . MAIN OUTCOME MEASURES At baseline , after 1 and 2 yr of GH treatment , fasting levels of adiponectin , glucose , insulin , and triglycerides were assessed . Body composition and fat distribution were measured by dual energy x-ray absorptiometry . RESULTS PWS children had significantly higher median ( interquartile range ) adiponectin levels [ 17.1 mg/liter ( 13.9 - 23.2 ) ] than healthy sex- and age-matched controls [ 11.8 mg/liter ( 9.7 - 12.5 ) , P<0.005 ] . Body fat percentage was significantly higher than 0 sd score [ 1.8 sd score ( 1.5 - 2.1 ) , P<0.001 ] . Adiponectin levels were inversely related to triglyceride levels ( r=-0.52 , P=0.03 ) . There was a tendency to an inverse relation with body fat percentage and body mass index , but no correlation with fasting insulin or glucose levels , the insulin to glucose ratio , or homeostasis model assessment index . During GH treatment , adiponectin levels increased significantly and did not change in r and omized controls . CONCLUSION Adiponectin levels were increased , and inversely associated with triglyceride levels , in prepubertal , not overweight PWS children , although they had a relatively high body fat percentage . During GH treatment , adiponectin levels further increased , whereas no change was found in the controls , which is reassuring with respect to the development of insulin resistance during GH treatment
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .